|
May 31
|
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
|
|
May 30
|
ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial
|
|
May 30
|
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
|
|
May 30
|
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
|
|
May 30
|
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
|
|
May 30
|
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
|
|
May 29
|
Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results
|
|
May 29
|
Moderna suffers a $750 million loss from NIH funding cut
|
|
May 29
|
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
|
|
May 28
|
Merck (NYSE:MRK) Declares US$0.81 Dividend for Q3 2025 Payout
|
|
May 27
|
Merck Announces Third-Quarter 2025 Dividend
|
|
Apr 3
|
Pharma Stocks Aren't in the Clear, Despite Tariff Exemption—Heard on the Street
|
|
Apr 2
|
3 Dividend Stocks To Consider With Yields Up To 4.2%
|
|
Apr 2
|
Wall Street Analysts Think Merck (MRK) Is a Good Investment: Is It?
|
|
Apr 2
|
The Zacks Analyst Blog Highlights Amazon.com, Oracle and Merck
|
|
Apr 1
|
Top Analyst Reports for Amazon, Oracle & Merck
|
|
Apr 1
|
Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call April 24
|
|
Mar 31
|
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
|
|
Mar 31
|
Merck (NYSE:MRK) Reports Strong Phase 3 Results For WINREVAIR In PAH Treatment
|
|
Mar 31
|
WINREVAIR™ (sotatercept-csrk) Reduced the Risk of a Composite of All-Cause Death, Lung Transplantation and Hospitalization for Pulmonary Arterial Hypertension (PAH) by 76% Compared to Placebo in the Phase 3 ZENITH Trial
|